2X1:ETR
Abivax SA
76,90 €
arrow_downward
-1,98%(-1,55) 1D
13 հոկ, 17:35:42 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2X1...
Open
77,30 €
High
78,00 €
Low
75,90 €
Mkt. cap
6,77 մլրդ
Avg. vol.
1,79 հզր
Volume
2,48 հզր
52-wk high
137,40 €
52-wk low
60,85 €
EPS
-5,20 €
No. of employees
98
Open
77,30 €
High
78,00 €
Low
75,90 €
Mkt. cap
6,77 մլրդ
Avg. vol.
1,79 հզր
Volume
2,48 հզր
52-wk high
137,40 €
52-wk low
60,85 €
EPS
-5,20 €
No. of employees
98
News stories
From web sources and news partners
Idéal Investisseur
·
9 ժամ առաջ
Abivax stock breaks below its 77.10 € support level despite Goldman Sachs buying recommendation
https://www.dars.gov.et/
·
4 օր առաջ
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded04 դեկ, 2013 թ.
Headquarters-
Sector-
Websiteabivax.com